2024
Predictors of unsuccessful tuberculosis treatment outcomes in Brazil: an analysis of 259,484 patient records
Ryuk D, Pelissari D, Alves K, Oliveira P, Castro M, Cohen T, Sanchez M, Menzies N. Predictors of unsuccessful tuberculosis treatment outcomes in Brazil: an analysis of 259,484 patient records. BMC Infectious Diseases 2024, 24: 531. PMID: 38802744, PMCID: PMC11129366, DOI: 10.1186/s12879-024-09417-7.Peer-Reviewed Original ResearchConceptsTreatment outcomesFactors associated with unsuccessful treatment outcomesHigher risk of poor treatment outcomeTB treatmentRisk of poor treatment outcomesUnsuccessful treatmentEffectiveness of TB treatmentAssociated with unsuccessful treatmentUnsuccessful treatment outcomesTuberculosis treatment outcomesDrug-susceptible TBHealth system levelMultivariate logistic regression modelService-related factorsTB drug resistanceComorbid health conditionsHealth-related behaviorsCategorizing treatment outcomesPatient-level factorsClinical examination resultsNational Disease Notification SystemPoor treatment outcomesDisease notification systemHIV infectionLogistic regression modelsImpact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
James L, Klaassen F, Sweeney S, Furin J, Franke M, Yaesoubi R, Chesov D, Ciobanu N, Codreanu A, Crudu V, Cohen T, Menzies N. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis. PLOS Medicine 2024, 21: e1004401. PMID: 38701084, PMCID: PMC11101189, DOI: 10.1371/journal.pmed.1004401.Peer-Reviewed Original ResearchQuality-adjusted life yearsStandard of careDrug susceptibility testingRifampicin-resistant tuberculosisRR-TBEnd-of-treatmentLonger regimensTreatment strategiesTreatment outcomesBurden of drug-resistant TBCost-effective treatment strategyResistance to amikacinDrug-resistant TBSevere adverse eventsHistory of TBResistance to delamanidTB drug resistanceAnti-TB drugsLifetime costsAssociated treatment outcomesFQ-R.Average timeNatural history of TBFluoroquinolone resistanceFQ-R
2022
Budget impact of next-generation sequencing for diagnosis of TB drug resistance in Moldova
Cates L, Codreanu A, Ciobanu N, Fosburgh H, Allender C, Centner H, Engelthaler D, Crudu V, Cohen T, Menzies N. Budget impact of next-generation sequencing for diagnosis of TB drug resistance in Moldova. The International Journal Of Tuberculosis And Lung Disease 2022, 26: 963-969. PMID: 36163669, DOI: 10.5588/ijtld.22.0104.Peer-Reviewed Original ResearchConceptsPhenotypic drug susceptibility testingConventional phenotypic drug susceptibility testingTB drug resistanceDrug resistanceNext-generation sequencingTB treatment regimensNational TB ProgrammeDrug resistance testingMTB/RIFDrug susceptibility testingBudget impact analysisMajority of costsFeasibility of NGSTB programsTreatment regimensBudget impactSusceptibility testingRoutine useResistance testingStudy periodTesting volume
2016
Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic
Kunkel A, Crawford FW, Shepherd J, Cohen T. Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic. AIDS 2016, 30: 2715-2723. PMID: 27782966, PMCID: PMC5089846, DOI: 10.1097/qad.0000000000001235.Peer-Reviewed Original ResearchConceptsContinuous isoniazid preventive therapyIsoniazid preventive therapyIsoniazid-resistant tuberculosisTB epidemicPreventive therapyEffective TB treatmentLatent TB infectionTB drug resistanceTransmission dynamic modelTB infectionMortality benefitTB treatmentHIV controlHIV incidenceTB incidenceTB transmissionCase findingDrug resistanceIncidenceTuberculosisInitial benefitPLHIVHIVTherapyEpidemicUse of Lot Quality Assurance Sampling to Ascertain Levels of Drug Resistant Tuberculosis in Western Kenya
Jezmir J, Cohen T, Zignol M, Nyakan E, Hedt-Gauthier BL, Gardner A, Kamle L, Injera W, Carter EJ. Use of Lot Quality Assurance Sampling to Ascertain Levels of Drug Resistant Tuberculosis in Western Kenya. PLOS ONE 2016, 11: e0154142. PMID: 27167381, PMCID: PMC4864281, DOI: 10.1371/journal.pone.0154142.Peer-Reviewed Original ResearchConceptsMDR-TBDrug resistanceResistant tuberculosisLot Quality Assurance Sampling methodologyMulti-drug resistant tuberculosisPositive TB patientsDrug resistance surveillanceDrug-resistant tuberculosisTB drug resistanceRural settingsPoly-resistant strainsTB patientsWestern KenyaLot Quality AssuranceLow prevalencePatientsResistance surveillancePrevalenceTuberculosisLQASSettingLow levelsDifferent geographic settingsUrban settingsLevels
2013
Risk factors and timing of default from treatment for non-multidrug-resistant tuberculosis in Moldova
Jenkins HE, Ciobanu A, Plesca V, Crudu V, Galusca I, Soltan V, Cohen T. Risk factors and timing of default from treatment for non-multidrug-resistant tuberculosis in Moldova. The International Journal Of Tuberculosis And Lung Disease 2013, 17: 373-380. PMID: 23407226, PMCID: PMC3710709, DOI: 10.5588/ijtld.12.0464.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntitubercular AgentsContinuity of Patient CareFemaleHumansInstitutionalizationLeast-Squares AnalysisLinear ModelsMaleMedication AdherenceMoldovaMultivariate AnalysisPatient DischargePrisonersProportional Hazards ModelsRetrospective StudiesRisk FactorsSocioeconomic FactorsTime FactorsTreatment OutcomeTuberculosisConceptsMultidrug-resistant tuberculosisMDR-TB patientsRisk factorsHighest MDR-TB ratesDrug resistanceGreater lung pathologyMDR-TB ratesAnti-tuberculosis treatmentIndependent risk factorHuman immunodeficiency virusTB drug resistanceContinuity of careRoutine surveillance dataTuberculosis patientsResistant tuberculosisImmunodeficiency virusLung pathologyTreatment adherenceRetrospective analysisHigh riskPatientsSociodemographic factorsCommunity careSurveillance dataStudy period